Get the Stockscreener App
18.49
4.88%
0.86
After Hours:
18.49
Kodiak Sciences Inc stock is traded at $18.49, with a volume of 450.63K.
It is up +4.88% in the last 24 hours and up +55.77% over the past month.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
See More
Previous Close:
$17.63
Open:
$18.38
24h Volume:
450.63K
Relative Volume:
0.52
Market Cap:
$976.67M
Revenue:
-
Net Income/Loss:
$-197.68M
P/E Ratio:
-4.9176
EPS:
-3.76
Net Cash Flow:
$-158.88M
1W Performance:
-0.38%
1M Performance:
+55.77%
6M Performance:
+390.45%
1Y Performance:
+275.81%
1-Day Range:
$18.19
$19.06
1-Week Range:
$15.83
$19.26
52-Week Range:
$1.92
$21.17
Kodiak Sciences Inc Stock (KOD) Company Profile
Name
Kodiak Sciences Inc
Sector
Industry
Phone
650-281-0850
Address
1200 PAGE MILL RD, PALO ALTO, CA
Compare KOD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
18.49 | 931.25M | 0 | -197.68M | -158.88M | -3.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.20 | 103.89B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
654.74 | 69.11B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.70 | 58.49B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
869.83 | 52.62B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
191.92 | 40.46B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-25-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Sep-22-25 | Initiated | Jefferies | Buy |
| Aug-14-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| Dec-11-23 | Resumed | Goldman | Sell |
| Nov-17-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Jul-25-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jul-25-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jul-24-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-15-22 | Initiated | CapitalOne | Overweight |
| Aug-02-22 | Downgrade | Citigroup | Neutral → Sell |
| Feb-24-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-11-22 | Initiated | Goldman | Buy |
| Feb-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-12-21 | Initiated | Evercore ISI | Outperform |
| Mar-01-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-17-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Nov-30-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-03-20 | Initiated | Goldman | Buy |
| Feb-18-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-06-20 | Initiated | SunTrust | Buy |
| Jan-08-20 | Initiated | ROTH Capital | Buy |
| Jan-03-20 | Initiated | Jefferies | Buy |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-20-19 | Initiated | Chardan Capital Markets | Buy |
| Oct-29-18 | Initiated | Barclays | Overweight |
| Oct-29-18 | Initiated | BofA/Merrill | Buy |
| Oct-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Kodiak Sciences Inc Stock (KOD) Latest News
Best data tools to analyze Kodiak Sciences Inc. stockJuly 2025 Volume & Fast Gaining Stock Reports - newser.com
Is Kodiak Sciences Inc. (K27) stock testing key supportQuarterly Investment Review & AI Enhanced Execution Alerts - newser.com
How Kodiak Sciences Inc. (K27) stock valuation compares with sectorWeekly Profit Recap & High Win Rate Trade Tips - newser.com
Does Kodiak Sciences Inc. show high probability of reboundQuarterly Profit Report & AI Based Buy and Sell Signals - newser.com
Chart based exit strategy for Kodiak Sciences Inc.2025 Retail Activity & Long-Term Safe Investment Plans - newser.com
Chart overlay techniques for tracking Kodiak Sciences Inc.Quarterly Earnings Report & Weekly Watchlist for Hot Stocks - newser.com
Published on: 2025-11-09 12:36:26 - newser.com
What candlestick patterns are forming on Kodiak Sciences Inc.Weekly Trend Summary & Daily Volume Surge Signals - newser.com
Should I hold or sell Kodiak Sciences Inc. stock in 2025Quarterly Earnings Summary & Community Consensus Stock Picks - newser.com
Applying Elliott Wave Theory to Kodiak Sciences Inc.July 2025 Chart Watch & Momentum Based Trading Ideas - newser.com
Can technical indicators confirm Kodiak Sciences Inc.’s reversalJuly 2025 Outlook & Fast Exit/Entry Strategy Plans - newser.com
Will Kodiak Sciences Inc. stock maintain growth story2025 Trading Recap & Low Risk High Reward Ideas - newser.com
Analyzing recovery setups for Kodiak Sciences Inc. investorsMarket Risk Analysis & Free Low Drawdown Momentum Trade Ideas - newser.com
Will Kodiak Sciences Inc. stock deliver consistent dividends2025 Market Trends & Weekly High Return Stock Forecasts - newser.com
What indicators show strength in Kodiak Sciences Inc.2025 Bull vs Bear & Stock Timing and Entry Methods - newser.com
How Kodiak Sciences Inc. stock reacts to Fed rate cutsJobs Report & AI Driven Stock Movement Reports - newser.com
Kodiak Sciences Inc. Announces Follow-Up Data for KSI-101 from the Apex Study - MarketScreener
Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI) - Sahm
Will Kodiak Sciences Inc. (K27) stock outperform foreign stocksJuly 2025 Breakouts & Safe Capital Growth Tips - newser.com
Is Kodiak Sciences Inc. stock a safe haven assetJuly 2025 Catalysts & Safe Investment Capital Preservation Plans - newser.com
How geopolitical risks impact Kodiak Sciences Inc. (K27) stock2025 AllTime Highs & Reliable Intraday Trade Alerts - newser.com
Is Kodiak Sciences Inc. stock ready for a breakoutRate Hike & Safe Entry Point Alerts - newser.com
Published on: 2025-11-03 06:58:55 - newser.com
How to manage a losing position in Kodiak Sciences Inc.Trade Entry Report & Weekly Chart Analysis and Guides - newser.com
Kodiak Sciences Inc Stock (KOD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):